Viracta Therapeutics (VIRX) News Today → Who are Nvidia’s New Silent Partners? (From Weiss Ratings) (Ad) Free VIRX Stock Alerts $0.70 +0.01 (+1.45%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 24, 2024 | americanbankingnews.comViracta Therapeutics (NASDAQ:VIRX) Price Target Cut to $11.00 by Analysts at OppenheimerMay 23, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Viracta Therapeutics (VIRX)May 18, 2024 | finanznachrichten.deViracta Therapeutics, Inc.: Viracta Therapeutics Announces New Employment Inducement GrantsMay 17, 2024 | globenewswire.comViracta Therapeutics Announces New Employment Inducement GrantsMay 14, 2024 | globenewswire.comViracta Therapeutics Appoints Michael Faerm as Chief Financial OfficerMay 10, 2024 | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on Viracta Therapeutics (VIRX)May 10, 2024 | investorplace.comVIRX Stock Earnings: Viracta Therapeutics Beats EPS for Q1 2024May 9, 2024 | globenewswire.comViracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 7, 2024 | globenewswire.comViracta Therapeutics to Present at the RBC Capital Markets Global Healthcare ConferenceApril 23, 2024 | msn.comDay One wins FDA nod for brain cancer therapy, OjemdaApril 18, 2024 | markets.businessinsider.comPromising Clinical Trial Results Reinforce Buy Rating for Viracta TherapeuticsApril 17, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Viracta Therapeutics (VIRX) and UnitedHealth (UNH)April 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM), Viracta Therapeutics (VIRX) and Bioxcel Therapeutics (BTAI)April 15, 2024 | msn.comWhy Is Small-Cap Cancer Drug Developer Viracta Therapeutics Stock Trading Lower On Monday?April 15, 2024 | globenewswire.comViracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell LymphomaApril 1, 2024 | globenewswire.comViracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of TaiwanMarch 22, 2024 | investing.comViracta Therapeutics CFO and COO Dan Chevallard resignsMarch 12, 2024 | markets.businessinsider.comBuy Rating for Viracta Therapeutics Backed by Upcoming Catalysts and Solid FinancialsMarch 8, 2024 | msn.comVIRX Stock Earnings: Viracta Therapeutics Misses EPS for Q4 2023March 7, 2024 | globenewswire.comViracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 29, 2024 | globenewswire.comViracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 TrialFebruary 17, 2024 | finance.yahoo.comVIRX Mar 2024 2.500 callFebruary 6, 2024 | finance.yahoo.comViracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceJanuary 4, 2024 | finance.yahoo.comViracta Therapeutics Provides Clinical Update and Outlook for 2024December 22, 2023 | benzinga.comViracta Therapeutics Stock (NASDAQ:VIRX) Dividends: History, Yield and DatesDecember 12, 2023 | msn.comViracta gets orphan drug status for Nana-val for EBV tumorsDecember 12, 2023 | finance.yahoo.comViracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal CarcinomaDecember 4, 2023 | finance.yahoo.comViracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose LevelsNovember 18, 2023 | morningstar.comViracta Therapeutics Inc VIRXNovember 9, 2023 | benzinga.comViracta Therapeutics: Q3 Earnings InsightsNovember 9, 2023 | finance.yahoo.comViracta Therapeutics Inc (VIRX) Reports Q3 2023 Financial Results Amid Clinical AdvancesNovember 9, 2023 | finance.yahoo.comViracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateOctober 5, 2023 | markets.businessinsider.comPromising Developments in Viracta Therapeutics Research and Trials Bolster Buy RatingOctober 4, 2023 | finance.yahoo.comViracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated CancersSeptember 5, 2023 | finance.yahoo.comViracta Therapeutics to Host R&D Day on October 4, 2023August 19, 2023 | finanznachrichten.deViracta Therapeutics, Inc.: Viracta Therapeutics Announces New Employment Inducement GrantAugust 15, 2023 | msn.comRBC Capital Reiterates Viracta Therapeutics (VIRX) Outperform RecommendationAugust 15, 2023 | markets.businessinsider.comExpert Ratings for Viracta TherapeuticsAugust 15, 2023 | markets.businessinsider.comRBC Capital Sticks to Their Buy Rating for Viracta Therapeutics (VIRX)August 15, 2023 | markets.businessinsider.comViracta Therapeutics (VIRX) Receives a Buy from H.C. WainwrightAugust 8, 2023 | finance.yahoo.comViracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) LymphomaAugust 7, 2023 | seekingalpha.comViracta Therapeutics gets new chief medical officerAugust 7, 2023 | markets.businessinsider.comViracta Therapeutics Names Darrel Cohen Chief Medical OfficerAugust 7, 2023 | finance.yahoo.comViracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical OfficerAugust 3, 2023 | msn.comViracta Therapeutics (VIRX) Price Target Decreased by 28.57% to 10.20July 19, 2023 | fool.comViracta Therapeutics (NASDAQ: VIRX)July 6, 2023 | msn.comViracta Therapeutics (VIRX) Price Target Decreased by 5.41% to 14.28July 5, 2023 | msn.comHC Wainwright & Co. Reiterates Viracta Therapeutics (VIRX) Buy RecommendationJune 28, 2023 | finance.yahoo.comViracta Therapeutics Says Pivotal Cancer Trial Achieves Efficacy Threshold For Expansion Into Next StageJune 28, 2023 | finance.yahoo.comViracta Therapeutics’ Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL) Get Viracta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Gift Could Unleash $51 Billion in New Wealth (Ad)In January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”. You just have to make this simple move before July 30, 2024. VIRX Media Mentions By Week VIRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VIRX News Sentiment▼1.140.76▲Average Medical News Sentiment VIRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VIRX Articles This Week▼11▲VIRX Articles Average Week Get Viracta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AMLX News CTXR News PDSB News COYA News IMUX News CRVO News VTGN News CLRB News BYSI News CLSD News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VIRX) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viracta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
